Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

Asia-Pacific shows higher patient recruitment rates for Oncology clinical trials

Asia-Pacific shows higher patient recruitment rates for Oncology clinical trials

November 15,2019

Biotechnology companies are facing tremendous challenges around patient recruitment, lengthy timeframes and high trial costs.

Asia-Pacific has become a preferred location for clinical studies because of lower trial density, large pools of patients, high number of active investigators, with efficient regulatory pathways.

The clinical activity of biotechnology companies in Oncology is estimated to have grown by 15% each year between 2016 and 2018, with the growth in the Asia-Pacific region estimated at over 40%.

For Industry-sponsored Oncology clinical studies initiated in 2018, trials involving the Asia-Pacific region showed a lower median enrolment duration (17% faster) compared with Oncology studies globally. Moreover, the median patient recruitment rate (measured in patient recruited per site per month) for the same sample of Oncology studies was about 50% higher for studies involving the Asia-Pacific region (1.38 p/s/m compared with 0.9 p/s/m globally).

Biotechnology companies looking for Oncology CRO services are increasingly turning to the Asia-Pacific region and looking for regional CRO specialists with a similar fit in terms of culture and flexibility.

As the region with the fastest-growing clinical activity, Asia is becoming increasingly attractive to European and North American biotechs. This progress in clinical trial activity is the result of a series of changes in the Asia-Pacific region in recent months.

Novotech relies on over 20 years of experience, deep in-country knowledge to identify and propose the best-performing sites and investigators for the Oncology study of biotechnology companies. Novotech’s experience covers numerous therapeutic areas especially:

  • Oncology CRO services, and Immuno-Oncology CRO services
  • Infectious diseases and Vaccines CRO services
  • Orphan and Rare diseases CRO services

Operational agility along with deep local knowledge of Asia Pacific location and strong relationships with sites, enables Novotech to propose high quality Oncology CRO services for biotechnology companies looking to accelerate their clinical trials at lower costs.